Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Telomere Length and Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia

    ... Telomere length in hematopoietic stem cell transplantation for severe aplastic anemia: is it ready for "prime time"? ...

    Research Review last updated 05/02/2016 - 9:13am.

  2. Youmna Kfoury, PhD

    ... platform of mesenchymal stromal layers and hematopoietic stem and progenitor cells (HSPCs) using a CRISPR-Cas9 based strategy to knock ... of MDS, the only curative therapy remains that of allogeneic stem cell transplant (allo-SCT). The allo-SCT is not the ...

    Grant Recipient last updated 12/15/2016 - 12:56pm.

  3. Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    ... trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic ... Intervention:  Biological: therapeutic allogeneic lymphocytes Given IV Other Name: ALLOLYMPH Other: laboratory ...

    Clinical Trial last updated 05/03/2016 - 11:17am.

  4. Overview of stem cell transplantation for aplastic anemia

    ... PubMed Abstract:  Allogeneic transplantation for aplastic anemia ... cyclosporine (CsA), or an allogeneic hematopoietic stem cell transplantation (Allo-HSCT).  An Allo-HSCT is a type of bone ...

    Research Review last updated 05/02/2016 - 9:31am.

  5. Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease (UF-BMT-MRD-101)

    ... MDS who have a small amount of detectable disease after allogeneic stem cell transplant . ...

    Clinical Trial last updated 04/29/2016 - 2:38pm.

  6. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... not eligible for, or opted not to participate in allogenic stem cell transplantation h. Off all other treatments for MDS (including ... of >30%) d.         Suitable candidate to receive allogeneic stem cell transplantation; patient is eligible for study if a ...

    Clinical Trial last updated 11/29/2016 - 8:29am.

  7. Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

    ... and about 50 percent of responders will relapse. Allogeneic bone marrow transplantation from either HLA -matched sibling ... disorders are not suitable candidates for hematopoietic stem cell transplantation (HSCT) due to advanced age or lack of a histocompatible ...

    Clinical Trial last updated 04/25/2016 - 2:18pm.

  8. Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

    ... disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological malignancies. Giving ... IV Other Names: Cellcept MMF Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Undergo nonmyeloablative ...

    Clinical Trial last updated 05/03/2016 - 9:44am.

  9. Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    ... that of patients undergoing haploidentical RIC hematopoietic stem cell transplantation (HSCT) as reported in the literature and as observed ... Transplantation Undergo PBSC transplant Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Undergo PBSC ...

    Clinical Trial last updated 04/27/2016 - 1:37pm.

  10. Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    ... This phase II trial studies how well donor peripheral blood stem cell (PBSC) transplant works in treating patients with hematologic ... who may benefit from tandem autologous-nonmyeloablative allogeneic transplant Left ventricular ejection fraction at rest must be >= ...

    Clinical Trial last updated 04/29/2016 - 3:26pm.